RV6 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong DSA Demand And BacklogGrowing bookings, backlog and book-to-bill indicate improving demand for outsourced discovery and safety services. This supports revenue visibility and reinforces CRL’s role as a recurring, specialized partner in pharmaceutical development.
Positive Cash GenerationPositive operating and free cash flow show that CRL’s regulated laboratory and research-services platform still converts activity into cash despite weak reported earnings. This provides funding for investment, debt service and operational resilience.
Expanding Capabilities And Service BreadthBroader capabilities in NGS, AI-enabled discovery and digital pathology can deepen customer relationships and increase CRL’s relevance across complex development workflows. These investments support differentiated expertise and longer-term outsourcing demand.
Bears Say
Severe Deterioration In Revenue And ProfitabilityThe swing from 11%–12% net margins in 2021–2023 to losses in 2025 and the TTM period indicates a material reduction in earnings power. Sustained cost pressure or weak demand could limit investment and financial flexibility.
Meaningful Leverage Amid LossesDebt is manageable relative to the asset base, but leverage becomes more restrictive when profitability and returns on equity are negative. Weaker earnings reduce the cushion for debt service and may constrain acquisitions or strategic investment.
RMS Weakness From Funding ConstraintsLower North American academic and government funding is reducing demand for small research models and related services. Continued grant pressure could prolong RMS weakness and offset growth in DSA and Manufacturing over the next several quarters.
RV6 FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Currently, no data Available
What is Charles River Laboratories Intl’s market cap?
Charles River Laboratories Intl’s market cap is CHF11.08B.
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Aug 05, 2026. The company reported CHF2.457 earnings per share for the quarter, beating the consensus estimate of CHF2.231 by CHF0.226.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is 2.41.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 47,738,873 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of CHF2.457 in its last earnings report, beating expectations of CHF2.231. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Currently, no hedge funds are holding shares in CH:RV6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charles River Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF227.44 (― Upside)
CHF227.44 (― Upside)
Blogger Sentiment
Neutral
CH:RV6 Sentiment 50%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth CHF2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.38%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
RV6 Company Deck
RV6 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear operational progress: better-than-expected Q2 results, sequential margin improvement (420 bps), stronger DSA demand signals with bookings/backlog gains and raised full-year guidance (organic revenue guidance improved by ~150 bps and EPS guidance raised). Strategic actions (divestitures, NHP supply integration, partnerships, AI/digital investments and lab expansions) are positioned to drive further margin and growth upside. However, notable near-term challenges remain: RMS softness driven by North American academic/government funding constraints, Q2 free cash flow decline, higher corporate costs and an elevated tax rate headwind, plus timing risk with material NHP sourcing benefits largely back-loaded into Q4 and pricing improvements not yet realized. On balance, positives (outperformance, raised guidance, bookings/backlog strength, margin momentum and strategic partnerships) outweigh the lowlights, though some operational and timing risks persist.View all CH:RV6 earnings summariesRV6 Revenue Breakdown
21.07% RMS
59.84% DSA
19.09% Manufacturing

RV6 Stock 12 Month Forecast
All Analysts
Top Analysts









